Tag: ace inhibitors market growth

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the ACE Inhibitors Market Evolve in Terms of Growth and Size by 2029?

The market of ACE inhibitors has seen stable growth in the past years. Its value is projected to increase from $7.15 billion in 2024 to $7.41 billion in 2025, indicating a compound annual growth rate (CAGR) of 3.6%. The significant growth during the historic period can be traced back to factors such as a surge in the occurrence of cardiovascular diseases, an increase in the elderly population, proven clinical effectiveness and safety, the spread of diabetes, as well as regulatory approval and guidelines.

In the coming years, the market size for ACE inhibitors is set to witness significant growth, reaching $9.42 billion by 2029, expanding at a compound annual growth rate (CAGR) of 6.2%. The upturn during the forecast period can be associated with the mounting global incidence of cardiovascular ailments, the enlargement of hypertension treatment guidelines, the progression of combination therapies, emphasis on heart failure management, and an increase in awareness and access to healthcare. Noteworthy trends expected during this period involve a concentration on kidney protection, a predilection for renin-angiotensin system inhibitors, generic competition and pricing challenges, patient-focused medical care practices, as well as regulatory modifications and safety assessments.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

What factors are expected to fuel ACE Inhibitors market growth in the coming years?

The growth of the ACE inhibitors market is being propelled by the rising incidence of hypertension disorders. Hypertension, often referred to in medical terms as high blood pressure, results from an increased pressure in the blood vessels. Angiotensin-converting enzyme inhibitors, commonly known as ACE inhibitors, are a group of drugs used to manage and treat this condition, functioning to relax the blood vessels and thereby reduce blood pressure and enhance blood circulation. As reported by the World Health Organization in March 2023, a Switzerland-based arm of the United Nations that specializes in global health matters, about 1.28 billion adults aged 30 to 79 worldwide suffered from hypertension, with two-thirds of this population living in low and middle-income countries. Over the past 30 years, an additional 650 million adults aged 30 to 79 have developed hypertension. Surprisingly, an estimated 46% of adults with hypertension have no knowledge of their condition due to lack of diagnosis. The number of adults aged 30-79 with hypertension has spiked by 650 million in the last 30 years. Approximately 46% of individuals suffering from hypertension remain oblivious to their condition because they haven’t been diagnosed. Consequently, the ACE inhibitors market is experiencing growth due to the escalating prevalence of hypertension disorders.

What Are The Key Findings From The Segmentation Analysis Of The ACE Inhibitors Market?

The ace inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril

Which Trends Are Expected To Shape The Future Of The ACE Inhibitors Market?

A primary trend gaining momentum in the ACE inhibitors market is the focus on product innovations. The leading corporations in this market channel their energies towards creating pioneering products to solidify their standing and get an edge in the competition. A case in point is Travere Therapeutics, a biopharmaceutical establishment from the United States, which received FDA approval for FILSPARI (sparsentan), a unique non-immunosuppressive therapy for patients with IgA nephropathy (IgAN) in February 2023. The therapy includes systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive drugs like angiotensin-receptor blockers (ARBs). It is the solitary non-immunosuppressive therapy that has been approved. An oral medication to be taken once daily, it is intended to treat adults with primary IgAN who are prone to fast disease progression and usually show a UPCR of less than 1.5 g/g and proteinuria.

What Are The Most Active Companies In The ACE Inhibitors Market Today?

Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Which Regional Markets Are Attracting The Most Investment In ACE Inhibitors?

North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the ACE Inhibitors Market Size Changed, over the years?

The market size for ACE inhibitors has been experiencing a consistent escalation in recent years. It is projected to expand from $7.15 billion in 2024 to $7.48 billion in 2025, recording a compound annual growth rate (CAGR) of 4.6%. This growth during the historic period is linked to several factors such as rising incidences of cardiovascular diseases, an increasing elderly population, clinical efficacy and safety standards, prevalence of diabetes, as well as endorsements and guidelines from regulatory authorities.

How Much Will the ACE Inhibitors Market Be Worth in 2029?

In the forthcoming years, the ACE inhibitors market is projected to experience robust growth, reaching $9.6 billion by 2029 with a compound annual growth rate (CAGR) of 6.4%. Factors contributing to this growth through the prediction period include the increasing worldwide prevalence of cardiovascular diseases, wider guidelines for hypertension treatment, enhancements in combination therapies, emphasis on managing heart failure, and improved healthcare access and awareness. Key trends anticipated during this period include a focus on protecting the kidneys, a preference for inhibitors of the renin-angiotensin system, generic competition and pricing pressures, patient-oriented healthcare practices, and regulatory changes and safety considerations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

Which is the Largest Company in the ACE Inhibitors Market?

Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

What Are the Main Market Drivers in the ACE Inhibitors Industry?

The spike in hypertension conditions is anticipated to fuel the expansion of the ACE inhibitors market. Hypertension, medically referred to as high blood pressure, is typified by heightened pressure within the blood vessels. Medicines known as ACE inhibitors, or angiotensin-converting enzyme inhibitors, are employed in managing and controlling this condition. These drugs work by easing the blood vessels, hence lowering blood pressure and enhancing blood circulation. As indicated by the World Health Organization, a Switzerland-based specialized agency of the United Nations, in March 2023, hypertension affected around 1.28 billion adults aged 30-79 globally, with most (two-thirds) living in low- and middle-income countries. Over the past three decades, the number of people in this age bracket suffering from hypertension has surged by 650 million. Interestingly, about 46% of adults suffering from hypertension are oblivious of their condition as they are yet to receive a diagnosis. Thus, the mounting incidence of hypertension-related disorders is triggering the ascent of the ACE inhibitors market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp

How Is the ACE Inhibitors Market Segments Structured?

The ACE inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril

What Strategic Trends Are Transforming the ACE Inhibitors Market?

A notable trend gaining traction in the ACE inhibitors market is the emphasis on product innovations. Leading businesses in this industry are concentrating on developing unique products to consolidate their market position and achieve a competitive edge. For example, Travere Therapeutics, a US-based biopharmaceutical company, received FDA approval in February 2023 for FILSPARI (sparsentan), a ground-breaking non-immunosuppressive treatment to be used in patients diagnosed with IgA nephropathy (IgAN). The treatment regimen includes systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive medications, such as angiotensin-receptor blockers (ARBs). It stands out for being the only approved non-immunosuppressive therapy that can be taken orally once daily, aimed at treating adults with primary IgAN who are prone to quick disease progression and generally exhibit a UPCR of less than 1.5 g/g and proteinuria.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Which Global Regions Offer the Highest Growth in the ACE Inhibitors Market?

North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10671

This Report Delivers Insight On:

1. How big is the ace inhibitors market, and how is it changing globally?

2. Who are the major companies in the ace inhibitors market, and how are they performing?

3. What are the key opportunities and risks in the ace inhibitors market right now?

4. Which products or customer segments are growing the most in the ace inhibitors market?

5. What factors are helping or slowing down the growth of the ace inhibitors market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the ACE Inhibitors Market Size Changed, over the years?

The market size for ACE inhibitors has been experiencing a consistent escalation in recent years. It is projected to expand from $7.15 billion in 2024 to $7.48 billion in 2025, recording a compound annual growth rate (CAGR) of 4.6%. This growth during the historic period is linked to several factors such as rising incidences of cardiovascular diseases, an increasing elderly population, clinical efficacy and safety standards, prevalence of diabetes, as well as endorsements and guidelines from regulatory authorities.

How Much Will the ACE Inhibitors Market Be Worth in 2029?

In the forthcoming years, the ACE inhibitors market is projected to experience robust growth, reaching $9.6 billion by 2029 with a compound annual growth rate (CAGR) of 6.4%. Factors contributing to this growth through the prediction period include the increasing worldwide prevalence of cardiovascular diseases, wider guidelines for hypertension treatment, enhancements in combination therapies, emphasis on managing heart failure, and improved healthcare access and awareness. Key trends anticipated during this period include a focus on protecting the kidneys, a preference for inhibitors of the renin-angiotensin system, generic competition and pricing pressures, patient-oriented healthcare practices, and regulatory changes and safety considerations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

Which is the Largest Company in the ACE Inhibitors Market?

Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

What Are the Main Market Drivers in the ACE Inhibitors Industry?

The spike in hypertension conditions is anticipated to fuel the expansion of the ACE inhibitors market. Hypertension, medically referred to as high blood pressure, is typified by heightened pressure within the blood vessels. Medicines known as ACE inhibitors, or angiotensin-converting enzyme inhibitors, are employed in managing and controlling this condition. These drugs work by easing the blood vessels, hence lowering blood pressure and enhancing blood circulation. As indicated by the World Health Organization, a Switzerland-based specialized agency of the United Nations, in March 2023, hypertension affected around 1.28 billion adults aged 30-79 globally, with most (two-thirds) living in low- and middle-income countries. Over the past three decades, the number of people in this age bracket suffering from hypertension has surged by 650 million. Interestingly, about 46% of adults suffering from hypertension are oblivious of their condition as they are yet to receive a diagnosis. Thus, the mounting incidence of hypertension-related disorders is triggering the ascent of the ACE inhibitors market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp

How Is the ACE Inhibitors Market Segments Structured?

The ACE inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril

What Strategic Trends Are Transforming the ACE Inhibitors Market?

A notable trend gaining traction in the ACE inhibitors market is the emphasis on product innovations. Leading businesses in this industry are concentrating on developing unique products to consolidate their market position and achieve a competitive edge. For example, Travere Therapeutics, a US-based biopharmaceutical company, received FDA approval in February 2023 for FILSPARI (sparsentan), a ground-breaking non-immunosuppressive treatment to be used in patients diagnosed with IgA nephropathy (IgAN). The treatment regimen includes systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive medications, such as angiotensin-receptor blockers (ARBs). It stands out for being the only approved non-immunosuppressive therapy that can be taken orally once daily, aimed at treating adults with primary IgAN who are prone to quick disease progression and generally exhibit a UPCR of less than 1.5 g/g and proteinuria.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Which Global Regions Offer the Highest Growth in the ACE Inhibitors Market?

North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10671

This Report Delivers Insight On:

1. How big is the ace inhibitors market, and how is it changing globally?

2. Who are the major companies in the ace inhibitors market, and how are they performing?

3. What are the key opportunities and risks in the ace inhibitors market right now?

4. Which products or customer segments are growing the most in the ace inhibitors market?

5. What factors are helping or slowing down the growth of the ace inhibitors market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the ace inhibitors industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The ACE Inhibitors Market Size Shifted, And What Is the Outlook Through 2034?

In recent times, the market size for ACE inhibitors has seen consistent growth. A rise from $7.15 billion in 2024 to $7.48 billion in 2025 is projected, demonstrating a compound annual growth rate (CAGR) of 4.6%. The historical growth can be linked to several factors, namely an increase in cardiovascular disease occurrence, a growing aging population, proven clinical efficacy and safety, diabetes prevalence, regulatory approvals and established guidelines.

The market size for ACE inhibitors is anticipated to experience robust growth in the upcoming years, reaching a value of $9.6 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 6.4%. The driving factors behind this projected growth for the forecasted period include an increased worldwide prevalence of cardiovascular diseases, broadened hypertension treatment guidelines, advancements in combined therapies, a heightened concentration on heart failure management, and increased accessibility and awareness of healthcare. Major trends that are expected to shape the landscape during the forecast period involve a focus on kidneys’ protection, favoring renin-angiotensin system inhibitors, competition from generic brands resulting in pricing pressures, patient-oriented strategies in healthcare, and modifications in regulations and safety aspects.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

Which Primay Drivers Are Accelerating Growth in the ACE Inhibitors Market?

The growth of the ACE inhibitors market is anticipated to be fuelled by the rising incidence of hypertension disorders. Hypertension, also known medically as high blood pressure, is defined by increased pressure levels in the blood vessels. ACE inhibitors, or angiotensin-converting enzyme inhibitors as they are often called, are a classification of drugs that are used in the management of hypertension. They work by relaxing the blood vessels, which in turn reduces blood pressure and enhances blood circulation. As per the World Health Organization, a United Nations specialized agency based in Switzerland, approximately 1.28 billion adults aged between 30 and 79 were diagnosed with hypertension across the globe as of March 2023. This group predominantly (two-thirds) consists of people living in low-to-middle income countries. Over the recent 30 years, a staggering increase of 650 million people between the ages 30 to 79 have been diagnosed with hypertension. Astonishingly, an estimated 46% of these adults remain unaware of their condition due to lack of diagnosis. Consequently, this rising prevalence of hypertension disorders is propelling the growth of the ACE inhibitors market.

Which Primary Segments of the ACE Inhibitors Market Are Driving Growth and Industry Transformations?

The ACE inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the ACE Inhibitors Market?# Market?

North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which Technological Trends Are Reshaping the ACE Inhibitors Industry Dynamics?

Emerging as a notable trend in the ACE inhibitors market space, product innovations are becoming increasingly important. Positioned on the goal of consolidating their hold and acquiring an edge over competitors, major firms in the ACE inhibitors market are committed to creating cutting-edge products. An example of this happened in February 2023 when Travere Therapeutics, an American biopharmaceutical entity, received FDA endorsement for FILSPARI (sparsentan). This novel non-immunosuppressive therapy is suited for IgA nephropathy (IgAN) patients. The treatment measures used include systemic glucocorticoids, ACE inhibitors, and antihypertensive drugs such as angiotensin-receptor blockers (ARBs). The standout feature of this therapy is its status as the only non-immunosuppressive treatment approved. It serves as a once-a-day oral medicine formulated for adults with primary IgAN, who are prone to quick disease progression and usually show a UPCR less than 1.5 g/g and proteinuria.

View the full report here:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

What Parameters Are Used to Define the ACE Inhibitors Market?

ACE inhibitors, also known as angiotensin-converting enzyme (ACE) inhibitors, refer to a type of medication used to treat and manage hypertension. They function by stopping the body’s enzyme from generating angiotensin II, a chemical that constricts blood vessels and raises blood pressure. Its basic function is to relax the veins and arteries to reduce blood pressure.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10671

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Are the Primary Drivers Supporting the Market Growth of theACE Inhibitors Market?

The escalating occurrence of high blood pressure ailments is projected to influence the expansion of the ACE inhibitors market. Hypertension, or high blood pressure, is a medical condition defined by an increased tension within the blood channels. ACE inhibitors, synonymous with angiotensin-converting enzyme inhibitors, are a class of drugs used to manage and control hypertension. They operate by calming the blood vessels, leading to a decrease in blood pressure and a betterment in blood circulation. For example, as per the data from the World Health Organization, a UN-affiliated agency based in Switzerland, about 1.28 billion adults between the ages of 30 and 79 dealt with hypertension globally in March 2023, with a majority, two-thirds to be precise, living in low-income to middle-income countries. Over the previous 30 years, there has been a surge of 650 million aged 30-79 people suffering from hypertension. There’s an estimated 46% of adults with hypertension who are unaware of their condition due to a lack of diagnosis. In the last three decades, an added 650 million adults between ages 30 and 79 have been diagnosed with hypertension, and roughly 46% of them remain undiagnosed or unaware of their condition. Hence, the escalating occurrence of hypertensive disorders is propelling the ACE inhibitors market expansion.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

#What Long-Term Growth Rate is Expected for theACE Inhibitors Market Between 2025 and 2034?

In the past few years, the market size for ACE inhibitors has been expanding consistently. It’s anticipated to expand from $7.15 billion in 2024 to $7.48 billion in 2025, with a compound annual growth rate (CAGR) of 4.6%. Numerous factors have contributed to this growth during the historical period, such as an increase in cases of cardiovascular disease, an aging population, effective clinical outcomes and safety profiles, a higher prevalence of diabetes, and regulatory approvals and guidelines.

The market for ACE inhibitors is predicted to experience significant growth in the upcoming years, with projections suggesting it will reach “$9.6 billion by the year 2029, with a compound annual growth rate (CAGR) of 6.4%. This anticipated growth during the forecast period is attributable to the increasing global prevalence of cardiovascular diseases, broader hypertension treatment protocols, progress in combination therapies, concentration on managing heart failure, and improved awareness and access to healthcare. Key trends forecasted for this period include an emphasis on kidney protection, a preference for renin-angiotensin system inhibitors, the competition and pricing pressures from generics, patient-oriented healthcare strategies, and updates in regulatory and safety measures.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10671

What Are the Latest Innovations Influencing theACE Inhibitors Market?

The ACE inhibitors market is witnessing a surge in product innovations, which is becoming a major trend. The key players in this market are striving to design and launch innovative products to solidify their market standing and acquire a leading edge over their competitors. For instance, in February 2023, the US-based biopharmaceutical corporation Travere Therapeutics received approval from FDA for FILSPARI (sparsentan), a unique non-immunosuppressive therapeutic curated for patients suffering from IgA nephropathy (IgAN). The treatments involved, including systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive medicines like angiotensin-receptor blockers (ARBs), make this the only non-immunosuppressive therapy approved to date. This once-daily oral treatment is intended for adults with primary IgAN who are at a high risk of rapid disease progression, typically exhibiting a UPCR less than 1.5 g/g and proteinuria.

Who Are the Major Industry Players Accelerating Growth in theACE Inhibitors Market?

Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Which Primary Segments of the ACE Inhibitors Market Are Driving Growth and Industry Transformations?

The ACE inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theACE Inhibitors Market?# Market?

North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Gobal ACE Inhibitors Maret 2025, By The Business Research Company:

Surveillance Technology Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/surveillance-technology-global-market-report

Synthetic Biology Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/synthetic-biology-global-market-report

Alpha Mannosidosis Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Factors Are Driving the Anticipated Growth Rate of the ACE Inhibitors Market Through 2034?

The market for ACE inhibitors has seen a consistent increase in size over the past few years. The market, which is valued at $7.15 billion in 2024, is projected to rise to $7.48 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.6%. The expanding rate in the preceding years can be credited to several factors including, an elevated incidence of cardiovascular ailments, a growing elderly population, proven clinical efficacy and safety, rising incidence of diabetes, and supportive regulatory approvals and guidelines.

In the coming years, the ACE inhibitors market is projected to witness robust expansion, estimated to reach “$9.6 billion by 2029, with a compound annual growth rate (CAGR) of 6.4%. This surge during the forecast period is largely due to the escalating global prevalence of cardiovascular ailments, broadening hypertension treatment protocols, advancements in combined therapies, emphasis on managing heart failure, and an upswing in awareness and access to healthcare. Key trends anticipated during the forecast period comprise focus on nephroprotection, a shift towards renin-angiotensin system inhibitors, rising generic competition and price constraints, adopting patient-focussed healthcare practices, and tweaks in regulations and safety measures.

What Drivers Are Shaping the Growth of the ace inhibitors Market?

The ACE inhibitors market is expected to grow due to the rising prevalence of hypertension disorders. Hypertension, commonly recognized as high blood pressure, is defined by increased pressure within the blood vessels. Angiotensin-converting enzyme inhibitors, better known as ACE inhibitors, are a cluster of drugs aimed at managing and controlling hypertension. They work by easing the blood vessels, thereby reducing blood pressure and enhancing blood circulation. As per the World Health Organization, a United Nations’ specialized agency based in Switzerland, nearly 1.28 billion adults aged between 30-79 suffered from hypertension globally in March 2023. The majority of these individuals lived in low- to middle-income countries. Over the past three decades, the count of people between 30-79 years with hypertension rose by 650 million. Intriguingly, 46% of adults suffering from hypertension are estimated to be unaware of their condition due to lack of proper diagnosis. This escalating occurrence of hypertension disorders is fueling the expansion of the ACE inhibitors market.

Get Your Free Sample of the Global ACE Inhibitors Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

Who Are the Major Industry Leaders Accelerating Growth in the ACE Inhibitors Market?

Major companies operating in the ACE inhibitors market include:

• Pfizer Inc._x000D_

• Novartis AG_x000D_

• Johnson & Johnson Private Limited_x000D_

• Merck KGaA_x000D_

• Sanofi S.A._x000D_

Which Current Trends Are Having the Most Impact on the ACE Inhibitors Market?

One primary trend shaping the field of ACE inhibitors is the focus on product innovations. Key players in the market are concentrating on the development of novel products in order to solidify their market positioning and gain an edge over their competitors. An example of this was in February 2023, when Travere Therapeutics, a biopharmaceutical firm from the United States, received FDA approval for FILSPARI (sparsentan). This unique non-immunosuppressive therapy is purposed for the treatment of patients with IgA nephropathy (IgAN). The therapy encompasses systematic glucocorticoids, ACE inhibitors, as well as antihypertensive drugs, inclusive of angiotensin-receptor blockers (ARBs). The standout feature of this therapy is its non-immunosuppressive nature and it is the only of its kind to be approved. It is a daily orally-taken medication, developed to be used by adults with primary IgAN who are at a high risk of accelerated disease progress and usually have a UPCR under 1.5 g/g, alongside proteinuria.

Get Instant Access to the Global ACE Inhibitors Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

What Are the Major Categories and Their Growth Dynamics in the ACE Inhibitors Market?

The ACE inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril

Which Regions Are Key Players in the Growth of the ACE Inhibitors Market?

North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Elements Shape the Definition of the ACE Inhibitors Market?

ACE inhibitors, also known as angiotensin-converting enzyme (ACE) inhibitors, refer to a type of medication used to treat and manage hypertension. They function by stopping the body’s enzyme from generating angiotensin II, a chemical that constricts blood vessels and raises blood pressure. Its basic function is to relax the veins and arteries to reduce blood pressure.

Browse Through More Similar Reports By The Business Research Company:

Surveillance Technology Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/surveillance-technology-global-market-report

Synthetic Biology Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/synthetic-biology-global-market-report

Alpha Mannosidosis Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: